Abstract
A fixed dose oral combination (FDC) of decitabine and cedazuridine (Inqovi(R)), is being developed by Astex Pharmaceuticals (a subsidiary of Otsuka Ph......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
